docetaxel
AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails
Truqap, capivasertib, AstraZeneca, Phase III trial failure, CAPItello-280, metastatic castration-resistant prostate cancer (mCRPC), AKT inhibitor, docetaxel, androgen-deprivation therapy (ADT), oncology setback, clinical trial discontinuation, radiographic progression-free survival, overall survival
Novocure’s Optune Lua Wins FDA Approval for Metastatic Non-Small Cell Lung Cancer Treatment
Novocure, Optune Lua, FDA approval, metastatic non-small cell lung cancer, TTFields, lung cancer treatment, PD-1/PD-L1 inhibitors, docetaxel.